Expert Opin Drug Saf. 2017 Apr;16(4):465-469. doi: 10.1080/14740338.2017.1300656. Epub 2017 Mar 8.
EGFR TKI combination with immunotherapy in non-small cell lung cancer
Ahn MJ11, Sun JM1, Lee SH1, Ahn JS1, Park K1.

Curr Opin Oncol. 2017 Mar;29(2):89-96. doi: 10.1097/CCO.0000000000000350.
Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
Sun JM11, Park K.

Ann Oncol. 2017 Mar 1;28(3):547-554. doi: 10.1093/annonc/mdw669.
Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition
Kim ST11, Kim SY1, Klempner SJ2,3, Yoon J4, Kim N4, Ahn S4,5, Bang H5,6, Kim KM5,6, Park W4, Park SH1, Park JO1, Park YS1, Lim HY1, Lee SH1, Park K1,6, Kang WK1, Lee J1.

RADIOTHERAPY AND ONCOLOGY, FEB 2017, 122(2):217-223, DOI: 10.1016/j.radonc.2016.09.015
A phase II trial of concurrent chemoradiotherapy with weekly docetaxel plus cisplatin treatment for unresectable locally advanced head and neck cancer
Lee JY1, Sun JM, Oh D, Lim SH, Chi S, Lee SH, Jung SH, Ahn MJ, Ahn YC, Park K

Ann Oncol. 2017 Feb 1;28(2):270-277. doi: 10.1093/annonc/mdw611.
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
Paz-Ares L11, Tan EH2, O'Byrne K3, Zhang L4, Hirsh V5, Boyer M6, Yang JC7, Mok T8, Lee KH9, Lu S10, Shi Y11, Lee DH12, Laskin J13, Kim DW14, Laurie SA15, Kolbeck K16, Fan J17, Dodd N18, Marten A19, Park K20.

Expert Opin Pharmacother. 2017 Feb;18(2):225-231. doi: 10.1080/14656566.2017.1285283.
Osimertinib for the treatment of non-small cell lung cancer
Sun JM11, Lee SH1, Ahn JS1, Park K1, Ahn MJ1.

Oncotarget. 2017 Jan 10;8(2):3542-3552. doi: 10.18632/oncotarget.12200.
Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery
Cho WK11, Oh D1, Ahn YC1, Shim YM2, Zo JI2, Sun JM3, Ahn MJ3, Park K3.

Oncotarget. 2017 Jan 10;8(2):3237-3245. doi: 10.18632/oncotarget.13700.
The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors
Lim SH11, Kim SY1, Kim K2, Jang H1, Ahn S2, Kim KM2, Kim NK3, Park W3, Lee SJ1, Kim ST1, Park SH1, Park JO1, Park YS1, Lee SH1, Lim HY1, Park K1, Kang WK1, Lee J1.

Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13.
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Rittmeyer A11, Barlesi F2, Waterkamp D3, Park K4, Ciardiello F5, von Pawel J6, Gadgeel SM7, Hida T8, Kowalski DM9, Dols MC10, Cortinovis DL11, Leach J12, Polikoff J13, Barrios C14, Kabbinavar F15, Frontera OA16, De Marinis F17, Turna H18, Lee JS19, Ballinger M3, Kowanetz M3, He P3, Chen DS3, Sandler A3, Gandara DR20; OAK Study Group.

J Thorac Oncol. 2016 Dec;11(12):2051-2052. doi: 10.1016/j.jtho.2016.09.130.
Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" Decision
Ahn MJ11, Sun JM2, Lee SH2, Ahn JS2, Park K2.

J Thorac Oncol. 2016 Dec;11(12):2202-2207. doi: 10.1016/j.jtho.2016.07.005. Epub 2016 Jul 14.
Do New pN Subclassifications Proposed by IASLC's Lung Cancer Staging Project Agree with ypN Categories after Trimodality Therapy for Initial N2 Disease?
Kim H11, Ahn YC2, Pyo H1, Oh D1, Noh JM1, Sun JM3, Ahn JS3, Ahn MJ3, Park K3, Choi YS4, Kim J4, Zo JI4, Shim YM4, Lee M5, Han J5.

Sci Rep. 2016 Nov 28;6:37392. doi: 10.1038/srep37392.
Vertical Magnetic Separation of Circulating Tumor Cells for Somatic Genomic-Alteration Analysis in Lung Cancer Patients
Yoo CE11,2, Park JM3, Moon HS1,2, Joung JG2, Son DS1,2, Jeon HJ2, Kim YJ1,2, Han KY1,2, Sun JM4, Park K4, Park D1,2, Park WY2,5.

World Neurosurg. 2016 Nov;95:399-405. doi: 10.1016/j.wneu.2016.08.046. Epub 2016 Aug 24.
Outcomes of Gamma Knife Radiosurgery in Combination with Crizotinib for Patients with Brain Metastasis from Non-Small Cell Lung Cancer
Choi JW11, Kong DS1, Seol HJ1, Nam DH1, Yoo KH2, Sun JM2, Ahn JS2, Ahn MJ2, Park K2, Lee JI3.

J Thorac Dis. 2016 Nov;8(11):3175-3186. doi: 10.21037/jtd.2016.11.25.
The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations
Cha YK11, Lee HY2, Ahn MJ3, Park K3, Ahn JS3, Sun JM3, Choi YL4, Lee KS2.

Invest New Drugs. 2016 Oct;34(5):625-35. doi: 10.1007/s10637-016-0368-1. Epub 2016 Jun 27.
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer
Scagliotti G11, Kang JH2, Smith D3, Rosenberg R4, Park K5, Kim SW6, Su WC7, Boyd TE8, Richards DA9, Novello S10, Hynes SM11, Myrand SP12, Lin J11, Smyth EN11, Wijayawardana S11, Lin AB11, Pinder-Schenck M13,14.

Cancer Res Treat. 2016 Oct;48(4):1177-1186. Epub 2016 Feb 22.
East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL)
Park K11, Kim JH2, Cho EK3, Kang JH4, Shih JY5, Zimmermann AH6, Lee P6, Alexandris E6, Puri T7, Orlando M8.

J Thorac Oncol. 2016 Oct;11(10):1736-44. doi: 10.1016/j.jtho.2016.05.038. Epub 2016 Jul 21.
A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma
Mok TS11, Geater SL2, Su WC3, Tan EH4, Yang JC5, Chang GC6, Han M7, Komarnitsky P7, Payumo F7, Garrus JE8, Close S8, Park K9.

Lung Cancer. 2016 Oct;100:24-29. doi: 10.1016/j.lungcan.2016.07.025. Epub 2016 Jul 26.
Value of volume-based early metabolic response in patients with unresectable thymic epithelial tumor
Moon SH11, Kim HS2, Cho YS1, Sun JM3, Ahn JS3, Park K3, Kim BT1, Ahn MJ4, Lee KH5.

Cancer. 2016 Oct;122(19):3024-31. doi: 10.1002/cncr.30135. Epub 2016 Jun 17.
Efficacy and Safety of Dovitinib in Pretreated Patients With Advanced Squamous Non-Small Cell Lung Cancer With FGFR1 Amplification: A Single-Arm, Phase 2 Study
Lim SH11, Sun JM1, Choi YL2, Kim HR3, Ahn S2, Lee JY1, Lee SH1, Ahn JS1, Park K1, Kim JH3, Cho BC4, Ahn MJ5.

Invest New Drugs. 2016 Aug;34(4):407-15. doi: 10.1007/s10637-016-0350-y. Epub 2016 Apr 5.
AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells
Ku BM11, Bae YH1, Koh J1, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3,4.

Med Oncol. 2016 Aug;33(8):97. doi: 10.1007/s12032-016-0811-3. Epub 2016 Jul 22.
Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis
Byeon S11, Ham JS1, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3.

LUNG CANCER, AUG 2016, 98:9-14, DOI: 10.1016/j.lungcan.2016.05.004
Characteristics, treatment patterns, and survival among ALK plus non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study
Cadranel J1, Park K, Arrieta O, Pless M, Bendaly E, Patel D, Sasane M, Nosal A, Swallow E, Galebach P

Lancet Oncol. 2016 Jul;17(7):e268-e269. doi: 10.1016/S1470-2045(16)30244-3.
LUX-Lung 7: is there enough data for a final conclusion? reply
1,Park K1.

Oncotarget. 2016 Jun 14;7(24):36311-36320. doi: 10.18632/oncotarget.8904.
Targeted sequencing identifies genetic alterations that confer Primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)
Lim SM11,2, Kim HR1, Cho EK3, Min YJ4, Ahn JS5, Ahn MJ5, Park K5, Cho BC1, Lee JH6, Jeong HC6, Kim EK6, Kim JH2.

Lung Cancer. 2016 Jun;96:56-62. doi: 10.1016/j.lungcan.2016.03.016. Epub 2016 Mar 29.
Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease
Kim HK11, Cho JH1, Choi YS1, Zo JI1, Shim YM1, Park K2, Ahn MJ2, Ahn YC3, Kim K4, Kim J5.

Lung Cancer. 2016 Jun;96:48-51. doi: 10.1016/j.lungcan.2016.03.012. Epub 2016 Mar 26.
Assessment of objective responses in thymic epithelial tumors using ITMIG modified criteria
Kim HS11, Lee JY2, Lim SH2, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3.

Lancet Oncol. 2016 May;17(5):577-89. doi: 10.1016/S1470-2045(16)30033-X. Epub 2016 Apr 12.
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Park K11, Tan EH2, O'Byrne K3, Zhang L4, Boyer M5, Mok T6, Hirsh V7, Yang JC8, Lee KH9, Lu S10, Shi Y11, Kim SW12, Laskin J13, Kim DW14, Arvis CD15, Kolbeck K16, Laurie SA17, Tsai CM18, Shahidi M19, Kim M20, Massey D19, Zazulina V19, Paz-Ares L21.

Clin Cancer Res. 2016 May 15;22(10):2386-95. doi: 10.1158/1078-0432.CCR-15-1260. Epub 2016 Jan 8.
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)
Karlovich C11, Goldman JW2, Sun JM3, Mann E1, Sequist LV4, Konopa K5, Wen W6, Angenendt P7, Horn L8, Spigel D9, Soria JC10, Solomon B11, Camidge DR12, Gadgeel S13, Paweletz C14, Wu L6, Chien S6, O'Donnell P6, Matheny S1, Despain D1, Rolfe L1, Raponi M1, Allen AR1, Park K3, Wakelee H15.

Clin Cancer Res. 2016 May 1;22(9):2139-45. doi: 10.1158/1078-0432.CCR-15-1653. Epub 2015 Dec 14.
A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib
Lee JY11, Sun JM1, Lim SH1, Kim HS, Yoo KH1, Jung KS1, Song HN1, Ku BM2, Koh J2, Bae YH2, Lee SH1, Ahn JS1, Park K1, Ahn MJ3.

Lancet. 2016 Apr 30;387(10030):1837-46. doi: 10.1016/S0140-6736(16)00587-0. Epub 2016 Mar 10.
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Fehrenbacher L11, Spira A2, Ballinger M3, Kowanetz M3, Vansteenkiste J4, Mazieres J5, Park K6, Smith D7, Artal-Cortes A8, Lewanski C9, Braiteh F10, Waterkamp D3, He P3, Zou W3, Chen DS3, Yi J3, Sandler A3, Rittmeyer A11; POPLAR Study Group.

J Thorac Oncol. 2016 Apr;11(4):453-74. doi: 10.1016/j.jtho.2016.01.012. Epub 2016 Jan 30.
Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes
Bunn PA Jr11, Minna JD2, Augustyn A2, Gazdar AF2, Ouadah Y3, Krasnow MA3, Berns A4, Brambilla E5, Rekhtman N6, Massion PP7, Niederst M8, Peifer M9, Yokota J10, Govindan R11, Poirier JT6, Byers LA12, Wynes MW13, McFadden DG2, MacPherson D14, Hann CL15, Farago AF8, Dive C16, Teicher BA17, Peacock CD18, Johnson JE2, Cobb MH2, Wendel HG6, Spigel D19, Sage J3, Yang P20, Pietanza MC6, Krug LM6, Heymach J12, Ujhazy P20, Zhou C21, Goto K22, Dowlati A23, Christensen CL24, Park K25, Einhorn LH26, Edelman MJ27, Giaccone G28, Gerber DE2, Salgia R29, Owonikoko T30, Malik S17, Karachaliou N31, Gandara DR32, Slotman BJ33, Blackhall F34, Goss G35, Thomas R9, Rudin CM6, Hirsch FR36.

Cancer Res Treat. 2016 Apr;48(2):527-36. doi: 10.4143/crt.2015.249. Epub 2015 Sep 15.
Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma
Kim HS11, Lee JY1, Lim SH1, Park K1, Sun JM1, Ko YH2, Baek CH3, Son YI3, Jeong HS3, Ahn YC4, Lee MY5, Hong M6, Ahn MJ1.

Cancer Res Treat. 2016 Apr;48(2):458-64. doi: 10.4143/crt.2015.135. Epub 2015 Oct 14.
Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial
Kang JH11, Ahn MJ2, Kim DW3, Cho EK4, Kim JH5, Shin SW6, Wang X7, Kim JS8, Orlando M9, Park K2.

Head Neck. 2016 Apr;38 Suppl 1:E293-9. doi: 10.1002/hed.23988. Epub 2015 Jun 26.
Fate of patients with nasopharyngeal cancer who developed distant metastasis as first failure after definitive radiation therapy
Chang JH11,2, Ahn YC1, Park H1, Oh D1, Noh JM1, Sun JM3, Ahn MJ3, Park K3.

Oncotarget. 2016 Mar 22;7(12):14803-13. doi: 10.18632/oncotarget.7543.
The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma
Ku BM11, Yi SY2, Koh J1, Bae YH1, Sun JM3, Lee SH3, Ahn JS3, Park K3, Ahn MJ3.

JOURNAL OF CLINICAL ONCOLOGY, MAR 1 2016, 34(7):768-+, DOI: 10.1200/JCO.2015.65.1042
Consolidation Chemotherapy After Concurrent Chemoradiotherapy in Patients With Stage III Non-Small-Cell Lung Cancer Reply
Ahn JS1, Park K

EXPERT OPINION ON BIOLOGICAL THERAPY, MAR 3 2016, 16(3):397-406 , DOI: 10.1517/14712598.2016.1145652
Pembrolizumab for the treatment of non-small cell lung cancer
Lim SH1, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ

Oncotarget. 2016 Mar 22;7(12):13797-809. doi: 10.18632/oncotarget.7318.
Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation
Kim N11,2, Cho A2, Watanabe H3,4, Choi YL2,5, Aziz M6, Kassner M6, Joung JG7, Park AK1,2, Francis JM8, Bae JS7, Ahn SM5, Kim KM5, Park JO9, Park WY2,7, Ahn MJ9, Park K9, Koo J10, Yin HH6, Cho J1,2,7.

Lung Cancer. 2016 Mar;93:95-103. doi: 10.1016/j.lungcan.2016.01.007. Epub 2016 Jan 19.
Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy
Perol M11, Ciuleanu TE2, Arrieta O3, Prabhash K4, Syrigos KN5, Goksel T6, Park K7, Kowalyszyn RD8, Pikiel J9, Lewanski CR10, Thomas M11, Dakhil S12, Kim JH13, Karaseva N14, Yurasov S15, Zimmermann A16, Lee P17, Carter GC18, Reck M19, Cappuzzo F20, Garon EB21.

J Thorac Oncol. 2016 Mar;11(3):370-9. doi: 10.1016/j.jtho.2015.11.008. Epub 2015 Dec 25.
First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study
Yang JC11, Srimuninnimit V2, Ahn MJ3, Lin CC4, Kim SW5, Tsai CM6, Mok T7, Orlando M8, Puri T9, Wang X10, Park K3.

Ann Oncol. 2016 Mar;27(3):417-23. doi: 10.1093/annonc/mdv597. Epub 2015 Dec 8.
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
Schuler M1, Yang JC, Park K, Kim JH, Bennouna J, Chen YM, Chouaid C, De Marinis F, Feng JF, Grossi F, Kim DW, Liu X, Lu S, Strausz J, Vinnyk Y, Wiewrodt R, Zhou C, Wang B, Chand VK, Planchard D; LUX-Lung 5 Investigators.

Cancer Imaging. 2016 Mar 16;16:5. doi: 10.1186/s40644-016-0063-7.
Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study
Lee JH11, Lee HY2, Ahn MJ3, Park K3, Ahn JS3, Sun JM3, Lee KS1.

JAMA Oncol. 2016 Mar;2(3):305-12. doi: 10.1001/jamaoncol.2015.4921.
First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer The ASPIRATION Study
Park K11, Yu CJ2, Kim SW3, Lin MC4, Sriuranpong V5, Tsai CM6, Lee JS7, Kang JH8, Chan KC9, Perez-Moreno P10, Button P11, Ahn MJ1, Mok T12.

Oncotarget. 2016 Feb 9;7(6):6984-93. doi: 10.18632/oncotarget.6874.
Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)
Lee JY11, Qing X2, Xiumin W2, Yali B2, Chi S3, Bak SH4, Lee HY5, Sun JM1, Lee SH1, Ahn JS1, Cho EK6, Kim DW7, Kim HR8, Min YJ9, Jung SH3, Park K1, Mao M2, Ahn MJ1.

Radiother Oncol. 2016 Feb;118(2):244-50. doi: 10.1016/j.radonc.2015.11.030. Epub 2015 Dec 17.
Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02)
Lee JY11, Sun JM1, Oh DR2, Lim SH1, Goo J3, Lee SH1, Kim SB4, Park KU5, Kim HK6, Hong DS7, Kim JS8, Kim SG9, Yi SY10, Yun HJ11, Hyun MS12, Kim HJ13, Jung SH3, Park K1, Ahn YC14, Ahn MJ15.

Biomaterials. 2016 Jan;75:271-8. doi: 10.1016/j.biomaterials.2015.10.033. Epub 2015 Oct 23.
Highly dense, optically inactive silica microbeads for the isolation and identification of circulating tumor cells
Yoo CE11, Moon HS1, Kim YJ1, Park JM1, Park D1, Han KY1, Park K2, Sun JM2, Park WY3.

Support Care Cancer. 2016 Jan;24(1):301-9. doi: 10.1007/s00520-015-2783-9. Epub 2015 Jun 4.
Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects
Hwang IG11, Kang JH2, Oh SY3,4, Lee S5, Kim SH5, Song KH6, Son C7, Park MJ8, Kang MH2, Kim HG2, Lee J9, Park YS9, Sun JM9, Kim HJ10, Kim CK10, Yi SY11, Jang JS1, Park K12,13, Kim HJ5.

Jpn J Clin Oncol. 2016 Jan;46(1):40-5. doi: 10.1093/jjco/hyv163. Epub 2015 Nov 10.
Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy: implication for subgroup selection for induction chemotherapy
Lim SH11, Lee SJ1, Ahn MJ1, Park K1, Sun JM2.

Eur J Cancer. 2016 Jan;52:1-9. doi: 10.1016/j.ejca.2015.09.019. Epub 2015 Nov 26.
Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer
Lim SH11, Hong M2, Ahn S3, Choi YL3, Kim KM3, Oh D4, Ahn YC4, Jung SH5, Ahn MJ1, Park K1, Zo JI6, Shim YM6, Sun JM7.

Oncotarget. 2015 Dec 29;6(42):44971-84. doi: 10.18632/oncotarget.6056.
Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma
Kim HS11, Kim SM2, Kim H3, Pyo KH2, Sun JM4, Ahn MJ4, Park K4, Keam B5, Kwon NJ6, Yun HJ7, Kim HG8, Chung IJ9, Lee JS10, Lee KH11, Kim DJ12, Lee CG13, Hur J14, Chung H15, Park JC15, Shin SK15, Lee SK15, Kim HR1, Moon YW1, Lee YC15, Kim JH1, Paik S16,17, Cho BC1.

J Thorac Oncol. 2015 Dec;10(12):1667-9. doi: 10.1097/JTO.0000000000000701.
The MISSION Impossible No, the Journey Should Continue with Better Targeting!
Lee SH11, Park K.

J Thorac Oncol. 2015 Dec;10(12):1800-6. doi: 10.1097/JTO.0000000000000692.
A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors
Kim HS11, Lee JY, Lim SH, Sun JM, Lee SH, Ahn JS, Park K, Moon SH, Ahn MJ.

Oncotarget. 2015 Nov 24;6(37):40360-9. doi: 10.18632/oncotarget.5465.
Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients
Kim ST11, Lee WS2, Lanman RB3, Mortimer S3, Zill OA3, Kim KM4,5, Jang KT5, Kim SH5, Park SH1, Park JO1,4, Park YS1, Lim HY1, Eltoukhy H3, Kang WK1, Lee WY6, Kim HC6, Park K1,4, Lee J1,4, Talasaz A3.

J Neurooncol. 2015 Nov;125(2):331-8. doi: 10.1007/s11060-015-1915-x. Epub 2015 Sep 15.
Outcome of gamma knife radiosurgery for metastatic brain tumors derived from non-small cell lung cancer
Cho KR11, Lee MH1, Kong DS1, Seol HJ1, Nam DH1, Sun JM2, Ahn JS2, Ahn MJ2, Park K2, Kim ST3, Lim do H4, Lee JI5.

Oncotarget. 2015 Nov 17;6(36):39028-35. doi: 10.18632/oncotarget.5494.
NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line
Lee SJ11, Li GG2, Kim ST1, Hong ME3, Jang J1, Yoon N3, Ahn SM3, Murphy D2, Christiansen J2, Wei G2, Hornby Z2, Lee DW4, Park JO1,5, Park YS1, Lim HY1, Hong SN6, Kim SH3, Kang WK1, Park K1, Park WY7, Kim KM3,5, Lee J1.

Lung Cancer. 2015 Nov;90(2):261-6. doi: 10.1016/j.lungcan.2015.08.020. Epub 2015 Sep 4.
Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs
Lee SJ11, Sun JM1, Lee SH1, Ahn JS1, Park K1, Ahn MJ2.

Oncotarget. 2015 Oct 20;6(32):33358-68. doi: 10.18632/oncotarget.5188.
The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis
Kim ST11, Lee J1, Hong M2,3, Park K4,5, Park JO1, Ahn T3,4, Park SH1, Park YS1, Lim HY1, Sun JM1, Ahn JS1, Ahn MJ1, Kim HC6, Sohn TS6, Choi DI7, Cho JH8, Heo JS6, Kwon W6, Uhm SW9, Lee H10, Min BH10, Hong SN10, Kim DH5,11, Jung SH12, Park W4,5, Kim KM2,3, Kang WK1, Park K1,2.

Cancer Res Treat. 2015 Oct;47(4):871-8. doi: 10.4143/crt.2014.141. Epub 2015 Feb 13.
Role of Chemotherapy in Stacie II Nasopharyngeal Carcinoma Treated with Curative Radiotherapy
Kang MK11, Oh D2, Cho KH3, Moon SH3, Wu HG4, Heo DS5, Ahn YC2, Park K6, Park HJ2, Park JS2, Keum KC7, Cha J7, Kim JW7, Kim YS8, Kang JH9, Oh YT10, Kim JY11, Kim SH12, Kim JH13, Lee CG7.

Cancer Res Treat. 2015 Oct;47(4):645-52. doi: 10.4143/crt.2014.144. Epub 2015 Feb 12.
Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer
Noh JM11, Ahn YC1, Lee H2, Pyo H1, Kim B1, Oh D1, Park H1, Lee E1, Park K3, Ahn JS3, Ahn MJ3, Sun JM3.

ONCOTARGET, OCT 13 2015, 6(31), 30929-30938, 10.18632/oncotarget.5131
Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer
Park S1, Langley E, Sun JM, Lockton S, Ahn JS, Jain A, Park K, Singh S, Kim P, Ahn MJ

Ann Oncol. 2015 Oct;26(10):2066-72. doi: 10.1093/annonc/mdv288. Epub 2015 Jul 7.
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
Yoshioka H11, Azuma K2, Yamamoto N3, Takahashi T4, Nishio M5, Katakami N6, Ahn MJ7, Hirashima T8, Maemondo M9, Kim SW10, Kurosaki M11, Akinaga S11, Park K7, Tsai CM12, Tamura T13, Mitsudomi T14, Nakagawa K15.

Oncotarget. 2015 Sep 29;6(29):28211-22. doi: 10.18632/oncotarget.4721.
Gastrointestinal malignancies harbor actionable MET exon 14 deletions
Lee J11,2, Ou SH3, Lee JM4, Kim HC5, Hong M6, Kim SY1, Jang J1, Ahn S6, Kang SY6, Lee S1, Kim ST1, Kim B4, Choi J4, Kim KA4, Lee J1, Park C1,6, Park SH1, Park JO1,2, Lim HY1, Kang WK1, Park K1,2, Park YS1, Kim KM2,6.

J Clin Oncol. 2015 Aug 20;33(24):2660-6. doi: 10.1200/JCO.2014.60.0130. Epub 2015 Jul 6.
Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04
Ahn JS11, Ahn YC1, Kim JH1, Lee CG1, Cho EK1, Lee KC1, Chen M1, Kim DW1, Kim HK1, Min YJ1, Kang JH1, Choi JH1, Kim SW1, Zhu G1, Wu YL1, Kim SR1, Lee KH1, Song HS1, Choi YL1, Sun JM1, Jung SH1, Ahn MJ1, Park K2.

PLoS Genet. 2015 Aug 21;11(8):e1005467. doi: 10.1371/journal.pgen.1005467. eCollection 2015.
Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer
Ji JH11, Oh YL2, Hong M2, Yun JW3, Lee HW2, Kim D4, Ji Y4, Kim DH4, Park WY3, Shin HT3, Kim KM2, Ahn MJ5, Park K5, Sun JM5.

J Clin Oncol. 2015 Aug 1;33(22):2450-6. doi: 10.1200/JCO.2014.59.9324. Epub 2015 Jun 29.
Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial
Sun JM11, Ahn JS1, Jung SH1, Sun J1, Ha SY1, Han J1, Park K1, Ahn MJ2.

Lancet Oncol. 2015 Jul;16(7):763-74. doi: 10.1016/S1470-2045(15)00021-2. Epub 2015 Jun 1.
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
Thatcher N1, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, B?lint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA; SQUIRE Investigators.

Clin Exp Otorhinolaryngol. 2015 Jun;8(2):142-8. doi: 10.3342/ceo.2015.8.2.142. Epub 2015 May 13.
Prognostic Value of Volume-Based Positron Emission Tomography/Computed Tomography in Patients With Nasopharyngeal Carcinoma Treated With Concurrent Chemoradiotherapy
Moon SH11, Choi JY1, Lee HJ1, Son YI2, Baek CH2, Ahn YC3, Ahn MJ4, Park K4, Kim BT1.

Cancer Chemother Pharmacol. 2015 Jun;75(6):1229-36. doi: 10.1007/s00280-015-2740-9. Epub 2015 Apr 23.
A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test
Choi MK11, Hong JY, Chang WJ, Kim MJ, Kim SM, Jung HA, Do IG, Choi YL, Sun JM, Ahn JS, Park K, Ahn MJ.

J Thorac Oncol. 2015 Jun;10(6):903-9. doi: 10.1097/JTO.0000000000000535.
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors
Lee JY11, Ku BM, Lim SH, Lee MY, Kim H, Kim M, Kim S, Jung HA, Sun JM, Ahn JS, Park K, Ahn MJ.

Head Neck. 2015 May;37(5):E66-9. doi: 10.1002/hed.23884. Epub 2015 Mar 29.
Presence of anaplastic lymphoma kinase translocation in sarcomatoid carcinoma of head and neck and treatment effect of crizotinib: A case series
Kim SM11, Kim MJ, Jung HA, Sun JM, Choi YL, Ko YH, Park K, Baek CH, Son YI, Ahn MJ.

Clin Lung Cancer. 2015 May;16(3):228-36. doi: 10.1016/j.cllc.2014.11.002. Epub 2014 Nov 18.
Survival Outcome Assessed According to Tumor Burden and Progression Patterns in Patients With Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma Undergoing Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
Cha YK11, Lee HY2, Ahn MJ3, Choi YL4, Lee JH1, Park K3, Lee KS1.

Ann Oncol. 2015 Apr;26(4):762-8. doi: 10.1093/annonc/mdu584. Epub 2014 Dec 23.
A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer
Lim SH11, Lee JY1, Lee MY1, Kim HS1, Lee J1, Sun JM1, Ahn JS1, Um SW2, Kim H2, Kim BS3, Kim ST4, Na DL5, Sun JY6, Jung SH7, Park K1, Kwon OJ2, Lee JI3, Ahn MJ8.

Mol Pharm. 2015 Apr 6;12(4):1230-41. doi: 10.1021/mp500737y. Epub 2015 Mar 7.
Tumor-Targeted Delivery of Paclitaxel Using Low Density Lipoprotein-Mimetic Solid Lipid Nanoparticles
Kim JH11,2, Kim Y1, Bae KH3, Park TG3, Lee JH2,4, Park K1,5.

Pharmacogenomics. 2015;16(4):383-91. doi: 10.2217/pgs.15.14.
Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients
Woo HI11, Kim JA, Jung HA, Kim KK, Lee JY, Sun JM, Ahn JS, Park K, Lee SY, Ahn MJ.

J Thorac Oncol. 2015 Mar;10(3):438-45. doi: 10.1097/JTO.0000000000000422.
EGFR Mutation Testing Practices within the Asia Pacific Region Results of a Multicenter Diagnostic Survey
Yatabe Y11, Kerr KM, Utomo A, Rajadurai P, Tran VK, Du X, Chou TY, Enriquez ML, Lee GK, Iqbal J, Shuangshoti S, Chung JH, Hagiwara K, Liang Z, Normanno N, Park K, Toyooka S, Tsai CM, Waring P, Zhang L, McCormack R, Ratcliffe M, Itoh Y, Sugeno M, Mok T.

J Thorac Oncol. 2015 Feb;10(2):331-7. doi: 10.1097/JTO.0000000000000388.
Endobronchial Ultrasound versus Mediastinoscopy for Mediastinal Nodal Staging of Non-Small-Cell Lung Cancer
Um SW11, Kim HK, Jung SH, Han J, Lee KJ, Park HY, Choi YS, Shim YM, Ahn MJ, Park K, Ahn YC, Choi JY, Lee KS, Suh GY, Chung MP, Kwon OJ, Kim J, Kim H.

Invest New Drugs. 2015 Feb;33(1):12-21. doi: 10.1007/s10637-014-0163-9. Epub 2014 Oct 25.
BYL719, a selective inhibitor of phosphoinositide 3-Kinase alpha, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer
Ku BM11, Jho EH, Bae YH, Sun JM, Ahn JS, Park K, Ahn MJ.

Lung Cancer. 2015 Feb;87(2):148-54. doi: 10.1016/j.lungcan.2014.11.013. Epub 2014 Nov 29.
Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: A retrospective analysis in Korea
Baek JH11, Sun JM2, Min YJ3, Cho EK4, Cho BC5, Kim JH5, Ahn MJ2, Park K2.

Cancer Chemother Pharmacol. 2015 Jan;75(1):77-85. doi: 10.1007/s00280-014-2619-1. Epub 2014 Nov 6.
Predictive factors for survival in stage IIIA N2 NSCLC patients treated with neoadjuvant CCRT followed by surgery
Lim HJ11, Lee HY, Lee KS, Han J, Kwon OJ, Park K, Ahn YC, Kim BT, Shim YM.

Ann Oncol. 2015 Jan;26(1):161-6. doi: 10.1093/annonc/mdu504. Epub 2014 Oct 29.
Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing
Sun JM11, Choi YL2, Ji JH3, Ahn JS1, Kim KM2, Han J2, Ahn MJ1, Park K4.

Korean J Intern Med. 2015 Jan;30(1):88-95. doi: 10.3904/kjim.2015.30.1.88. Epub 2014 Dec 30.
The efficacy of low-dose transdermal fentanyl in opioid-naive cancer patients with moderate-to-severe pain
Kang JH11, Oh SY2, Song SY3, Lee HY3, Kim JH4, Lee KE5, Lee HR6, Hwang IG7, Park SH8, Kim WS8, Park YS8, Park K8.

Small. 2015 Jan 14;11(2):222-31. doi: 10.1002/smll.201303277. Epub 2014 Aug 18.
Low-Density Lipoprotein-Mimicking Nanoparticles for Tumor-Targeted Theranostic Applications
Lee JY11, Kim JH, Bae KH, Oh MH, Kim Y, Kim JS, Park TG, Park K, Lee JH, Nam YS.

J Transl Med. 2014 Oct 25;12:299. doi: 10.1186/s12967-014-0299-6.
High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma
Ku BM1, Jung HA, Sun JM, Ko YH, Jeong HS, Son YI, Baek CH, Park K, Ahn MJ.

Lancet Oncol. 2014 Oct;15(11):1254-62. doi: 10.1016/S1470-2045(14)70402-4. Epub 2014 Sep 14.
Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data
Rossi A11, Chiodini P2, Sun JM3, O'Brien ME4, von Plessen C5, Barata F6, Park K3, Popat S4, Bergman B7, Parente B8, Gallo C2, Gridelli C9, Perrone F10, Di Maio M10.

J Thorac Oncol. 2014 Oct;9(10):1523-31. doi: 10.1097/JTO.0000000000000275.
Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non-Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib A Phase I/II Trial
Park K11, Cho BC, Kim DW, Ahn MJ, Lee SY, Gernhardt D, Taylor I, Campbell AK, Zhang H, Giri N, Letrent SP, O'Connell J, Heo DS.

Eur J Cancer. 2014 Sep;50(13):2219-30. doi: 10.1016/j.ejca.2014.05.011. Epub 2014 Jun 18.
First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
Yang JC11, Kang JH2, Mok T3, Ahn MJ4, Srimuninnimit V5, Lin CC1, Kim DW6, Tsai CM7, Barraclough H8, Altug S9, Orlando M10, Park K11.

Ann Oncol. 2014 Sep;25(9):1866. doi: 10.1093/annonc/mdu244. Epub 2014 Jul 15.
Letter to the editor on 'Phase III trial of concurrent thoracic radiotherapy with either first-or third-cycle chemotherapy for limited-disease small cell lung cancer'
Park K11, Sun JM2.

Lancet. 2014 Aug 23;384(9944):665-73. doi: 10.1016/S0140-6736(14)60845-X. Epub 2014 Jun 2.
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Garon EB11, Ciuleanu TE2, Arrieta O3, Prabhash K4, Syrigos KN5, Goksel T6, Park K7, Gorbunova V8, Kowalyszyn RD9, Pikiel J10, Czyzewicz G11, Orlov SV12, Lewanski CR13, Thomas M14, Bidoli P15, Dakhil S16, Gans S17, Kim JH18, Grigorescu A19, Karaseva N20, Reck M21, Cappuzzo F22, Alexandris E23, Sashegyi A24, Yurasov S23, P?rol M25.

Oncologist. 2014 Jul;19(7):702-3. doi: 10.1634/theoncologist.2013-0419. Epub 2014 May 27.
Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR
Ahn MJ11, Kim SW2, Cho BC3, Ahn JS1, Lee DH2, Sun JM1, Massey D4, Kim M5, Shi Y6, Park K7.

J Clin Oncol. 2014 Jul 1;32(19):2059-66. doi: 10.1200/JCO.2013.54.4932. Epub 2014 Jun 2.
Randomized, Phase III Trial of First-Line Figitumumab in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Advanced Non-Small-Cell Lung Cancer
Langer CJ11, Novello S2, Park K2, Krzakowski M2, Karp DD2, Mok T2, Benner RJ2, Scranton JR2, Olszanski AJ2, Jassem J2.

Cancer Chemother Pharmacol. 2014 Jun;73(6):1217-25. doi: 10.1007/s00280-014-2458-0. Epub 2014 Apr 3.
Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease
Choi MK11, Hong JY, Chang W, Kim M, Kim S, Jung HA, Lee SJ, Park S, Chung MP, Sun JM, Park K, Ahn MJ, Ahn JS.

Ann Surg Oncol. 2014 Jun;21(6):2083-90. doi: 10.1245/s10434-014-3540-x. Epub 2014 Feb 13.
Pretreatment Clinical Mediastinal Nodal Bulk and Extent do not Influence Survival in N2-Positive Stage IIIA Non-small Cell Lung Cancer Patients Treated with Trimodality Therapy
Lee H11, Ahn YC, Pyo H, Kim B, Oh D, Nam H, Lee E, Sun JM, Ahn JS, Ahn MJ, Park K, Choi YS, Kim J, Zo JI, Shim YM.

Cancer Chemother Pharmacol. 2014 May;73(5):1063-70. doi: 10.1007/s00280-014-2442-8. Epub 2014 Mar 25.
Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs
Lee JY11, Lim SH, Kim M, Kim S, Jung HA, Chang WJ, Choi MK, Hong JY, Lee SJ, Sun JM, Ahn JS, Park K, Ahn MJ.

Lung Cancer. 2014 Apr;84(1):51-5. doi: 10.1016/j.lungcan.2014.01.017. Epub 2014 Jan 28.
A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): Paclitaxel plus carboplatin versus vinorelbine plus cisplatin
Chang WJ11, Sun JM2, Lee JY1, Ahn JS1, Ahn MJ1, Park K1.

J Thorac Oncol. 2014 Apr;9(4):506-11. doi: 10.1097/JTO.0000000000000095.
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non-Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either Exon 19 or 21
Lim SH11, Lee JY, Sun JM, Ahn JS, Park K, Ahn MJ.

CANCER IMAGING, APR 22 2014, 14, 10.1186/1470-7330-14-2
Prognostic value of volumetric metabolic parameters measured by [F-18]Fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer
Park1, SB, Choi, JY, Moon, SH, Yoo, J, Kim, H, Ahn, YC, Ahn, MJ, Park, K, Kim, BT

Lung Cancer. 2014 Feb;83(2):259-64. doi: 10.1016/j.lungcan.2013.11.009. Epub 2013 Nov 20.
Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma
Sun JM11, Lira M2, Pandya K2, Choi YL3, Ahn JS1, Mao M2, Han J3, Park K1, Ahn MJ4, Kim J5.

Ann Oncol. 2014 Feb;25(2):529-36. doi: 10.1093/annonc/mdt552. Epub 2014 Jan 13.
Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis
Kubota K11, Ichinose Y, Scagliotti G, Spigel D, Kim JH, Shinkai T, Takeda K, Kim SW, Hsia TC, Li RK, Tiangco BJ, Yau S, Lim WT, Yao B, Hei YJ, Park K.

J Clin Oncol. 2014 Jan 10;32(2):121-8. doi: 10.1200/JCO.2013.50.8556. Epub 2013 Dec 9.
Integrative and Comparative Genomic Analysis of Lung Squamous Cell Carcinomas in East Asian Patients
Kim Y11, Hammerman PS, Kim J, Yoon JA, Lee Y, Sun JM, Wilkerson MD, Pedamallu CS, Cibulskis K, Yoo YK, Lawrence MS, Stojanov P, Carter SL, McKenna A, Stewart C, Sivachenko AY, Oh IJ, Kim HK, Choi YS, Kim K, Shim YM, Kim KS, Song SY, Na KJ, Choi YL, Hayes DN, Kim J, Cho S, Kim YC, Ahn JS, Ahn MJ, Getz G, Meyerson M, Park K.

Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):50-8. doi: 10.1007/s00259-013-2530-8. Epub 2013 Aug 16.
Volume-based assessment by F-18-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer
Hyun SH11, Ahn HK, Kim H, Ahn MJ, Park K, Ahn YC, Kim J, Shim YM, Choi JY.

Lung Cancer. 2013 Nov;82(2):294-8. doi: 10.1016/j.lungcan.2013.08.023. Epub 2013 Sep 3.
Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors
Sun JM11, Ahn MJ, Choi YL, Ahn JS, Park K.

Br J Cancer. 2013 Sep 17;109(6):1482-7. doi: 10.1038/bjc.2013.467. Epub 2013 Aug 20.
A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer
Sun JM11, Kim JR, Do IG, Lee SY, Lee J, Choi YL, Ahn JS, Ahn MJ, Park K.

Genomics. 2013 Sep;102(3):157-62. doi: 10.1016/j.ygeno.2013.02.006. Epub 2013 Feb 20.
Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment
Huang D11, Kim DW, Kotsakis A, Deng S, Lira P, Ho SN, Lee NV, Vizcarra P, Cao JQ, Christensen JG, Kim TM, Sun JM, Ahn JS, Ahn MJ, Park K, Mao M.

Biosens Bioelectron. 2013 Aug 15;46:142-9. doi: 10.1016/j.bios.2013.02.037. Epub 2013 Mar 6.
Rapid detection of exon 2-deleted AIMP2 mutation as a potential biomarker for lung cancer by molecular beacons
Jo SM11, Kim Y, Jeong YS, Hee Oh Y, Park K, Kim HS.

Macromol Biosci. 2013 Aug;13(8):1059-71. doi: 10.1002/mabi.201300046. Epub 2013 Jul 5.
The Effect of N/P Ratio on the In Vitro and In Vivo Interaction Properties of PEGylated Poly[2-(dimethylamino)ethyl methacrylate]-Based siRNA Complexes
Gary DJ11, Min J, Kim Y, Park K, Won YY.

Ann Oncol. 2013 Aug;24(8):2088-92. doi: 10.1093/annonc/mdt140. Epub 2013 Apr 16.
Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer(dagger)
Sun JM11, Ahn YC, Choi EK, Ahn MJ, Ahn JS, Lee SH, Lee DH, Pyo H, Song SY, Jung SH, Jo JS, Jo J, Sohn HJ, Suh C, Lee JS, Kim SW, Park K.

J Thorac Oncol. 2013 Jul;8(7):959-66. doi: 10.1097/JTO.0b013e318292c41e.
A Prospective Phase II Trial of Induction Chemotherapy with Docetaxel/Cisplatin for Masaoka Stage III/IV thymic Epithelial Tumors
Park S11, Ahn MJ, Ahn JS, Sun JM, Shim YM, Kim J, Choi YS, Kim K, Shin S, Ahn Y, Kwon OJ, Kim H, Lee SJ, Chang WJ, Park K.

PLoS One. 2013 May 28;8(5):e64816. doi: 10.1371/journal.pone.0064816. Print 2013.
Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer
Sun JM11, Hwang DW, Ahn JS, Ahn MJ, Park K.

J Thorac Oncol.?2013 Feb;8(2):250-3. doi: 10.1097/JTO.0b013e3182746772.
Successful Treatment with Crizotinib in Mechanically Ventilated Patients with ALK Positive Non-Small-Cell Lung Cancer
Ahn HK11,?Jeon K,?Yoo H,?Han B,?Lee SJ,?Park H,?Lee MJ,?Ha SY,?Han JH,?Sun JM,?Ahn JS,?Ahn MJ,?Park K.

J Mol Diagn. 2013 Jan;15(1):51-61. doi: 10.1016/j.jmoldx.2012.08.006. Epub 2012 Dec 12.
Multiplexed Gene Expression and Fusion Transcript Analysis to Detect ALK Fusions in Lung Cancer
Lira ME11, Kim TM, Huang D, Deng S, Koh Y, Jang B, Go H, Lee SH, Chung DH, Kim WH, Schoenmakers EF, Choi YL, Park K, Ahn JS, Sun JM, Ahn MJ, Kim DW, Mao M.

J Clin Oncol. 2012 Sep 20;30(27):3337-44. doi: 10.1200/JCO.2011.40.9433. Epub 2012 Jul 2.
Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer
Ramalingam SS11, Blackhall F, Krzakowski M, Barrios CH, Park K, Bover I, Seog Heo D, Rosell R, Talbot DC, Frank R, Letrent SP, Ruiz-Garcia A, Taylor I, Liang JQ, Campbell AK, O'Connell J, Boyer M.

Lung Cancer. 2012 Aug;77(2):339-45. doi: 10.1016/j.lungcan.2012.03.012. Epub 2012 Apr 10.
Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: A subanalysis of the phase III, randomized SATURN study
Wu YL11, Kim JH, Park K, Zaatar A, Klingelschmitt G, Ng C.

Lung Cancer. 2012 Aug;77(2):376-82. doi: 10.1016/j.lungcan.2012.03.010. Epub 2012 Apr 11.
Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study
Pirker R11, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Eberhardt WE, de Marinis F, Heeger S, Goddemeier T, O'Byrne KJ, Gatzemeier U.

Lung Cancer. 2012 Aug;77(2):365-70. doi: 10.1016/j.lungcan.2012.04.009. Epub 2012 May 11.
Chemotherapy for pulmonary large cell neuroendocrine carcinoma: Similar to that for small cell lung cancer or non-small cell lung cancer
Sun JM11, Ahn MJ, Ahn JS, Um SW, Kim H, Kim HK, Choi YS, Han J, Kim J, Kwon OJ, Shim YM, Park K.

J Clin Oncol. 2012 Aug 10;30(23):2829-36. doi: 10.1200/JCO.2011.41.4987. Epub 2012 Jul 2.
International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: MONET1
Scagliotti GV11, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F, Pirker R, Galiulin R, Ciuleanu TE, Sydorenko O, Dediu M, Papai-Szekely Z, Banaclocha NM, McCoy S, Yao B, Hei YJ, Galimi F, Spigel DR.

Lung Cancer. 2012 May;76(2):253-4. doi: 10.1016/j.lungcan.2012.02.003. Epub 2012 Mar 3.
ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis
Ahn HK11, Han B, Lee SJ, Lim T, Sun JM, Ahn JS, Ahn MJ, Park K.

Lancet Oncol. 2012 May;13(5):528-38. doi: 10.1016/S1470-2045(12)70087-6. Epub 2012 Mar 26.
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Miller VA11, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, Heo DS, Crino L, Tan EH, Chao TY, Shahidi M, Cong XJ, Lorence RM, Yang JC.

J Clin Oncol. 2012 Apr 1;30(10):1114-21. doi: 10.1200/JCO.2011.36.1709. Epub 2012 Feb 27.
Vandetanib Versus Placebo in Patients With Advanced Non-Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)
Lee JS11, Hirsh V, Park K, Qin S, Blajman CR, Perng RP, Chen YM, Emerson L, Langmuir P, Manegold C.

J Clin Oncol. 2012 Apr 1;30(10):1122-8. doi: 10.1200/JCO.2011.36.8456. Epub 2012 Feb 27.
First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
Han JY11, Park K, Kim SW, Lee DH, Kim HY, Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, Lee JS, Yoon SJ, Han JH, Lee JW, Jo SJ, Lee JS.

Hum Genet.?2012 Mar;131(3):365-72. doi: 10.1007/s00439-011-1080-z. Epub 2011 Aug 25.
The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations
Ahn MJ11,?Won HH,?Lee J,?Lee ST,?Sun JM,?Park YH,?Ahn JS,?Kwon OJ,?Kim H,?Shim YM,?Kim J,?Kim K,?Kim YH,?Park JY,?Kim JW,?Park K.

Mol Cancer Ther. 2012 Mar;11(3):784-91. doi: 10.1158/1535-7163.MCT-11-0750. Epub 2012 Jan 6.
The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor
Kim Y11, Ko J, Cui Z, Abolhoda A, Ahn JS, Ou SH, Ahn MJ, Park K.

Cancer Chemother Pharmacol. 2012 Feb;69(2):341-50. doi: 10.1007/s00280-011-1697-6. Epub 2011 Jul 8.
Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies
Thertulien R11, Manikhas GM, Dirix LY, Vermorken JB, Park K, Jain MM, Jiao JJ, Natarajan J, Parekh T, Zannikos P, Staddon AP.

Ann Oncol. 2012 Feb;23(2):388-94. doi: 10.1093/annonc/mdr125. Epub 2011 May 24.
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy
Coudert B11, Ciuleanu T, Park K, Wu YL, Giaccone G, Brugger W, Gopalakrishna P, Cappuzzo F; SATURN Investigators.

Lancet Oncol. 2012 Jan;13(1):33-42. doi: 10.1016/S1470-2045(11)70318-7. Epub 2011 Nov 4.
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
Pirker R11, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE, Paz-Ares L, St?rkel S, Schumacher KM, von Heydebreck A, Celik I, O'Byrne KJ.

BMC Cancer. 2011 Oct 7;11:430. doi: 10.1186/1471-2407-11-430.
INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer
Wu YL11, Park K, Soo RA, Sun Y, Tyroller K, Wages D, Ely G, Yang JC, Mok T.

Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):655-60. doi: 10.1016/j.ijrobp.2010.02.061.
EXPRESSION OF EXCISION REPAIR CROSS-COMPLEMENTATION GROUP 1 AS PREDICTIVE MARKER FOR NASOPHARYNGEAL CANCER TREATED WITH CONCURRENT CHEMORADIOTHERAPY
Sun JM11, Ahn MJ, Park MJ, Lee HY, Ahn JS, Lee S, Kang G, Han J, Son YI, Baek CH, Ahn YC, Park K.

ACS Nano. 2011 May 24;5(5):3493-505. doi: 10.1021/nn102540y. Epub 2011 Apr 6.
Influence of Nano-Carrier Architecture on in Vitro siRNA Delivery Performance and in Vivo Biodistribution: Polyplexes vs Micelleplexes
Gary DJ11, Lee H, Sharma R, Lee JS, Kim Y, Cui ZY, Jia D, Bowman VD, Chipman PR, Wan L, Zou Y, Mao G, Park K, Herbert BS, Konieczny SF, Won YY.

Ann Oncol. 2011 Feb;22(2):417-23. doi: 10.1093/annonc/mdq355. Epub 2010 Aug 9.
A phase II study of combination chemotherapy with capecitabine and cisplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck
Won YW11, Park YH, Ahn MJ, Do IG, Ko YH, Park K.

J Thorac Oncol. 2010 Oct;5(10):1609-15. doi: 10.1097/JTO.0b013e3181e15d55.
Efficacy and Safety of Erlotinib in 1242 East/South-East Asian Patients with Advanced Non-small Cell Lung Cancer
Mok T11, Wu YL, Au JS, Zhou C, Zhang L, Perng RP, Park K.

Jpn J Clin Oncol. 2010 Sep;40 Suppl 1:i7-12. doi: 10.1093/jjco/hyq121.
Lung Cancer Working Group Report
Saijo N11, Fukuoka M, Thongprasert S, Ichinose Y, Mitsudomi T, Mok TS, Ohe Y, Park K, Wu YL.

J Mol Diagn. 2010 Sep;12(5):644-52. doi: 10.2353/jmoldx.2010.090208.
Rapid Detection of the Epidermal Growth Factor Receptor Mutation in Non-Small-Cell Lung Cancer for Analysis of Acquired Resistance Using Molecular Beacons
Oh YH11, Kim Y, Kim YP, Seo SW, Mitsudomi T, Ahn MJ, Park K, Kim HS.

J Thorac Oncol.?2010 Aug;5(8):1185-96. doi: 10.1097/JTO.0b013e3181e2f624.
Korean Ethnicity as Compared with White Ethnicity Is an Independent Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer before and after the Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Era
Ahn MJ11,?Lee J,?Park YH,?Ahn JS,?Ziogas A,?Zell JA,?Park K,?Ou SH.

Lung Cancer. 2010 Jun;68(3):420-6. doi: 10.1016/j.lungcan.2009.07.011. Epub 2009 Aug 18.
A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer
Scagliotti GV11, Germonpre P, Bosquee L, Vansteenkiste J, Gervais R, Planchard D, Reck M, De Marinis F, Lee JS, Park K, Biesma B, Gans S, Ramlau R, Szczesna A, Makhson A, Manikhas G, Morgan B, Zhu Y, Chan KC, von Pawel J.

J Thorac Oncol. 2010 May;5(5):688-95. doi: 10.1097/JTO.0b013e3181d1273d.
Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung Cancer Results of an Exploratory Subgroup Analysis of a Phase III Trial
Yang CH11, Simms L, Park K, Lee JS, Scagliotti G, Orlando M.

J Thorac Oncol. 2010 Apr;5(4):540-5. doi: 10.1097/JTO.0b013e3181d3504d.
Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer Implications for Selection of Patients for Maintenance Therapy
Sun JM11, Park JO, Won YW, Kim JH, Yun J, Lee J, Park YH, Ahn JS, Ahn MJ, Park K.

J Thorac Oncol. 2010 Mar;5(3):369-75. doi: 10.1097/JTO.0b013e3181cee24f.
Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer
Chiappori A11, Bepler G, Barlesi F, Soria JC, Reck M, Bearz A, Barata F, Scagliotti G, Park K, Wagle A, Liepa AM, Zhao YD, Chouaki N, Iscoe N, von Pawel J.

Clin Cancer Res. 2010 Feb 15;16(4):1307-14. doi: 10.1158/1078-0432.CCR-09-1903. Epub 2010 Feb 9.
Randomized Phase III Trial of Gefitinib versus Docetaxel in Non-Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy
Lee DH11, Park K, Kim JH, Lee JS, Shin SW, Kang JH, Ahn MJ, Ahn JS, Suh C, Kim SW.

Cancer. 2010 Jan 1;116(1):132-6. doi: 10.1002/cncr.24719.
Multicenter Phase 2 Study of Belotecan, a New Camptothecin Analog, and Cisplatin for Chemotherapy-Naive Patients With Extensive-Disease Small Cell Lung Cancer
Lee DH11, Kim SW, Suh C, Lee JS, Ahn JS, Ahn MJ, Park K, Na II, Lee JC, Ryoo BY, Yang SH.

Lung Cancer. 2009 Dec;66(3):338-43. doi: 10.1016/j.lungcan.2009.02.008. Epub 2009 Mar 18.
Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: A prospective, multicenter trial
Lee HY11, Ahn MJ, Park YH, Ahn JS, Kim BS, Kim HK, Kim HT, Ryoo HM, Bae SH, Lee SS, Choi K, Hong DS, Lee KH, Kwon JH, Choi IS, Kim BS, Lee NS, Gong SJ, Park K.

Proteomics. 2009 Dec;9(24):5544-52. doi: 10.1002/pmic.200800777.
Protein profiling in human sera for identification of potential lung cancer biomarkers using antibody microarray
Han MK11, Oh YH, Kang J, Kim YP, Seo S, Kim J, Park K, Kim HS.

Cancer Chemother Pharmacol. 2009 Oct;64(5):917-24. doi: 10.1007/s00280-009-0943-7. Epub 2009 Feb 17.
Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer
Chang MH11, Kim KH, Jun HJ, Kim HS, Yi SY, Uhm JE, Park MJ, Lim do H, Ji SH, Hwang IG, Lee J, Park YH, Ahn JS, Ahn MJ, Park K.

J Thorac Oncol. 2009 Sep;4(9):1136-43. doi: 10.1097/JTO.0b013e3181b270a7.
Erlotinib Monotherapy for Stage IIIB/IV Non-small Cell Lung Cancer A Multicenter Trial by the Korean Cancer Study Group
Uhm JE11, Park BB, Ahn MJ, Lee J, Ahn JS, Kim SW, Kim HT, Lee JS, Kang JH, Cho JY, Song HS, Park SH, Sohn CH, Shin SW, Choi JH, Park K.

Eur J Cancer. 2009 Sep;45(13):2298-303. doi: 10.1016/j.ejca.2009.04.033. Epub 2009 May 25.
Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaive patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study
Scagliotti GV11, Park K, Patil S, Rolski J, Goksel T, Martins R, Gans SJ, Visseren-Grul C, Peterson P.

Cancer Res Treat. 2009 Jun;41(2):80-6. doi: 10.4143/crt.2009.41.2.80. Epub 2009 Jun 30.
Modest Anti-Cancer Activity of a Bile Acid Acylated Heparin Derivative in a PC14PE6 Induced Orthotopic Lung Cancer Model
Cui ZY11, Park MJ, Lee J, Ahn JS, Ahn MJ, Seo SW, Park JW, Byun Y, Park K.

Lancet. 2009 May 2;373(9674):1525-31. doi: 10.1016/S0140-6736(09)60569-9.
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Pirker R1, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U; FLEX Study Team.

APMIS. 2009 Feb;117(2):140-6. doi: 10.1111/j.1600-0463.2009.02433.x.
L1 cell adhesion molecule as a predictor for recurrence in pulmonary carcinoids and large-cell neuroendocrine tumors
Kim HS11, Yi SY, Jun HJ, Ahn JS, Ahn MJ, Lee J, Kim Y, Cui ZY, Hong HJ, Kim JM, Li S, Hwang IG, Park K.

Br J Cancer. 2008 Jul 8;99(1):167-72. doi: 10.1038/sj.bjc.6604464.
ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation
Jun HJ11, Ahn MJ, Kim HS, Yi SY, Han J, Lee SK, Ahn YC, Jeong HS, Son YI, Baek JH, Park K.

J Clin Oncol. 2008 Jul 20;26(21):3543-51. doi: 10.1200/JCO.2007.15.0375. Epub 2008 May 27.
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
Scagliotti GV11, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D.

Clin Cancer Res. 2008 Jun 15;14(12):3860-6. doi: 10.1158/1078-0432.CCR-07-4608.
Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer
Ahn MJ11, Park BB, Ahn JS, Kim SW, Kim HT, Lee JS, Kang JH, Cho JY, Song HS, Park SH, Sohn CH, Shin SW, Choi JH, Ki CS, Park CK, Holmes AJ, Janne PA, Park K.

Ann Oncol. 2008 Jan;19(1):123-7. Epub 2007 Sep 6.
Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study
Lee DH11, Kim SW, Suh C, Lee JS, Lee JH, Lee SJ, Ryoo BY, Park K, Kim JS, Heo DS, Kim NK.

Ann Oncol. 2007 Dec;18(12):2009-14. Epub 2007 Sep 4.
Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer
Kim DW11, Kim SY, Kim HK, Kim SW, Shin SW, Kim JS, Park K, Lee MY, Heo DS.

Cancer Lett. 2007 Dec 8;258(1):90-7.
Nongastric marginal zone B-cell lymphoma: A prognostic model from a retrospective multicenter study
Oh SY11, Kwon HC, Kim WS, Park YH, Kim K, Kim HJ, Kwon JM, Lee J, Ko YH, Ahn YC, Oh SJ, Lee SI, Bang SM, Kim JH, Park J, Ryoo BY, Lee SS, Kim HY, Park K, Kim HJ.

Biomaterials. 2007 Dec;28(36):5555-61. Epub 2007 Sep 29.
Nanoparticulate carrier containing water-insoluble iodinated oil as a multifunctional contrast agent for computed tomography imaging
Kong WH11, Lee WJ, Cui ZY, Bae KH, Park TG, Kim JH, Park K, Seo SW.

J Clin Oncol. 2007 Nov 20;25(33):5233-9.
Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small-cell lung cancer
Park JO11, Kim SW, Ahn JS, Suh C, Lee JS, Jang JS, Cho EK, Yang SH, Choi JH, Heo DS, Park SY, Shin SW, Ahn MJ, Lee JS, Yun YH, Lee JW, Park K.

Lung Cancer. 2007 Oct;58(1):116-22. Epub 2007 Jul 12.
Combination chemotherapy with paclitaxel and ifosfamide as the third-line regimen in patients with heavily pretreated small cell lung cancer
Park S11, Ahn MJ, Ahn JS, Lee J, Hong YS, Park BB, Lee SC, Hwang IG, Park JO, Lim H, Kang WK, Park K.

Br J Cancer. 2007 Jul 2;97(1):22-8. Epub 2007 Jun 26.
A single institutional experience of thymic epithelial tumours over 11 years: clinical features and outcome and implications for future management
Lee HS11, Kim ST, Lee J, Choi YS, Han JH, Ahn YC, Lee KS, Ahn JS, Ahn MJ, Kim K, Shim YM, Kim J, Park K.

Curr Ther Res Clin Exp. 2007 May;68(3):193-204. doi: 10.1016/j.curtheres.2007.06.004.
Clinical evaluation of incadronate in Korean patients with malignancy-associated hypercalcemia: An open-label, multicenter study
Kim SB11, Lee JS1, Kim HT2, Im YH3, Kim TW1, Ryoo BY2, Park YH2, Park JO3, Park K3, Katoh H4, Yamamoto M4.

Br J Cancer. 2006 Dec 18;95(12):1648-52. Epub 2006 Nov 28.
Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer
Hong YS11, Lee HR, Park S, Lee SC, Hwang IG, Park BB, Lee J, Ahn JS, Ahn MJ, Lim HY, Park K.

Leuk Lymphoma. 2006 Oct;47(10):2128-31.
High incidence of mucosa-associated lymphoid tissue in primary thyroid lymphoma: A clinicopathologic study of 18 cases in the Korean population
Cho JH11, Park YH, Kim WS, Oh SY, Cho SI, Kang HJ, Na II, Ryoo BY, Yang SH, Kim K, Jung CW, Park K, Ko YH, Lee SS.

Lung Cancer. 2006 Sep;53(3):323-30. Epub 2006 Jul 17.
Is trimodality approach better then bimodality in stage IIIA, N2 positive non-small cell lung cancer
Park BB11, Park JO, Kim H, Ahn YC, Choi YS, Kim K, Kim J, Shim YM, Ahn JS, Park K.

J Clin Oncol. 2006 Aug 20;24(24):4028-9.
Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after imatinib
Kim HJ11, Jung CW, Kim K, Ahn JS, Kim WS, Park K, Ko YH, Kang WK, Park K.

Ann Oncol. 2006 Jun;17(6):1000-6. Epub 2006 Mar 8.
Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment
Schmoll HJ11, Aapro MS, Poli-Bigelli S, Kim HK, Park K, Jordan K, von Pawel J, Giezek H, Ahmed T, Chan CY.

Ann Hematol. 2006 May;85(5):285-90. Epub 2006 Mar 4.
Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia
Park YH11, Kim WS, Kang HJ, Na II, Ryoo BY, Yang SH, Lee SS, Uhm JE, Kim K, Jung CW, Park K, Ko YH.

Lung Cancer. 2006 Apr;52(1):75-81. Epub 2006 Feb 20.
Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience
Kim JH11, Kim SY, Jung KH, Park K, Suh CW, Lim HY, Kim YH, Ryoo BY, Cho EK, Park BJ, Heo DS.

Curr Med Res Opin. 2006 Mar;22(3):561-73.
A review of the benefit risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer
Park K11, Goto K.

Cancer Chemother Pharmacol. 2006 Jan;57(1):91-6. Epub 2005 Nov 5.
Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer
Park SH11, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Kang WK, Park K, Kim S, Bang SM, Cho EK, Shin DB, Lee JH.

Hepatocellular carcinoma with metastasis to the breast
J Cell Biochem. 2005 Mar 1;94(4):695-707.
Arsenic trioxide represses constitutive activation of NF-kappa B and COX-2 expression in human acute myeloid leukemia, HL-60
Han SS11, Kim K, Hahm ER, Park CH, Kimler BF, Lee SJ, Lee SH, Kim WS, Jung CW, Park K, Kim J, Yoon SS, Lee JH, Park S.

Biol Blood Marrow Transplant. 2005 Feb;11(2):122-8.
Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission
Lee SH11, Lee MH, Lee JH, Min YH, Lee KH, Cheong JW, Lee J, Park KW, Kang JH, Kim K, Kim WS, Jung CW, Choi SJ, Lee JH, Park K.

Cell Signal. 2005 Jan;17(1):111-9.
Activation of Rafl and the ERK pathway in response to L-ascorbic acid in acute myeloid leukemia cells
Park S11, Park CH, Hahm ER, Kim K, Kimler BF, Lee SJ, Park HK, Lee SH, Kim WS, Jung CW, Park K, Riordan HD, Lee JH.

J Cell Biochem. 2004 Oct 1;93(2):257-70.
L-ascorbic acid represses constitutive activation of NF-kappa B and COX-2 expression in human acute myeloid leukemia, HL-60
Han SS11, Kim K, Hahm ER, Lee SJ, Surh YJ, Park HK, Kim WS, Jung CW, Lee MH, Park K, Yang JH, Yoon SS, Riordan NH, Riordan HD, Kimler BF, Park CH, Lee JH, Park S.

Clin Cancer Res. 2004 Jul 1;10(13):4383-8.
Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer
Park J11, Park BB, Kim JY, Lee SH, Lee SI, Kim HY, Kim JH, Park SH, Lee KE, Park JO, Kim K, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Park K.

Jpn J Clin Oncol. 2004 May;34(5):250-4.
Extrapulmonary small-cell carcinoma: a single-institution experience
Kim JH11, Lee SH, Park J, Kim HY, Lee SI, Nam EM, Park JO, Kim K, Jung CW, Im YH, Kang WK, Lee MH, Park K.

Jpn J Clin Oncol. 2003 Dec;33(12):620-5.
Early concurrent chemoradiotherapy with prolonged oral etoposide and cisplatin for limited-stage small-cell lung cancer
Lee SH11, Ahn YC, Kim HJ, Lim DH, Lee SI, Nam E, Park SH, Park J, Lee KE, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Lee MH, Park K.

Lung Cancer. 2003 Dec;42 Suppl 1:S17-9.
Consensus: the follow-up of the treated patient
Saunders M11, Sculier JP, Ball D, Capello M, Furuse K, Goldstraw P, Meert AP, Ninane V, Ohe Y, Paesmans M, Park K, Pirker R, Postmus P, Sokolow Y.

Lung Cancer. 2003 Nov;42(2):227-35.
A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers
Park J11, Ahn YC, Kim H, Lee SH, Park SH, Lee KE, Lim DH, Park J, Kim K, Jung CW, Im YH, Kang WK, Lee MH, Park K.

Bone Marrow Transplant. 2003 Nov;32(9):889-95.
Autologous peripheral blood stem cell transplantation with induction of autologous graft-versus-host disease in acute myeloid leukemia
Park J11, Lee MH, Lee HR, Park SH, Lee SH, Lee KE, Lee H, Park JO, Kim K, Jung CW, Im YH, Kang WK, Ko YH, Park K.

Jpn J Clin Oncol. 2003 Oct;33(10):509-13.
Vinorelbine, ifosfamide, and cisplatin combination as salvage chemotherapy in advanced non-small cell lung cancer
Song SY11, Kim WS, Kim K, Jung CW, Im YH, Kim HJ, Kang WK, Lee HG, Kwon OJ, Rhee CH, Park CH, Park K.

Jpn J Clin Oncol. 2003 Oct;33(10):533-7.
Measuring response in solid tumors: Comparison of RECIST and WHO response criteria
Park JO11, Lee SI, Song SY, Kim K, Kim WS, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Lee KS, Park K.

Lung Cancer. 2002 Nov;38(2):143-7.
Effects of transforming growth factor beta (TGF-beta) receptor on lung carcinogenesis
Park C11, Kim WS, Choi Y, Kim H, Park K.

Int J Cancer. 2002 Sep 20;101(3):235-42.
Monensin-mediated growth inhibition in acute myelogenous leukemia cells via cell cycle arrest and apoptosis
Park WH11, Lee MS, Park K, Kim ES, Kim BK, Lee YY.

Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):75-80.
Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in stage III non-small-cell lung cancer
Wu HG11, Bang YJ, Choi EK, Ahn YC, Kim YW, Lim TH, Suh C, Park K, Park CI.

Cytokine. 2001 Nov 7;16(3):102-5.
Implication of co-measured platelet factor 4 in the reliability of the results of the plasma transforming growth factor-beta 1 measurement
Jeon JH11, Kim YS, Choi EJ, Cheon S, Kim S, Kim JS, Jang JS, Ha WS, Park ST, Park CS, Park K, Park BK.

Ann Oncol. 2001 Mar;12(3):349-52.
CHOP followed by involved field radiation: Is it optimal for localized nasal natural killer/T-cell lymphoma
Kim WS11, Song SY, Ahn YC, Ko YH, Baek CH, Kim DY, Yoon SS, Lee HG, Kang WK, Lee HJ, Park CH, Park K.

Int J Oncol. 2000 Sep;17(3):473-8.
Deletion of one adenine base within the polyadenine tract of transforming growth factor-beta receptor type II in human MDA-MB-231 breast cancer cell line
Park B11, Jang JS, Park K.

Anticancer Res. 2000 May-Jun;20(3A):1499-502.
Microsatellite instability(MSI) in non-small cell lung cancer(NSCLC) is highly associated with transforming growth factor-beta type II receptor(TGF-beta RII) frameshift mutation
Kim WS11, Park C, Hong SK, Park BK, Kim HS, Park K.

Anticancer Res. 1999 Jan-Feb;19(1A):301-6.
Reduced transforming growth factor-beta type II receptor (TGF-beta RII) expression in adenocarcinoma of the lung
Kim WS11, Park C, Jung YS, Kim HS, Han J, Park CH, Kim K, Kim J, Shim YM, Park K.